Guerbet
Research Guerbet (GBT.PA) on Bullrun: market cap EUR 82.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGBT.PA
- ExchangeXPAR
- CountryFrance
- SectorHealthcare
- IndustryMedical Devices
- CurrencyEUR
- Market capEUR 82.68M
- Financial periodFY2025
- RevenueEUR 798.67M
- Revenue growth-6.2%
- Net income-EUR 108.33M
- Free cash flowEUR 44.48M
- Gross margin70.9%
Valuation Snapshot
latest market cap is EUR 82.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 798.67M | -EUR 108.33M | EUR 44.48M | 70.9% | n/a | EUR 115.52M | EUR 441.22M | EUR 267.00M |
| FY2024 | EUR 851.12M | EUR 16.08M | EUR 24.23M | 73.6% | 1.07 | EUR 50.24M | EUR 395.12M | EUR 394.24M |
| FY2023 | EUR 795.65M | EUR 23.87M | -EUR 26.61M | 74.0% | 1.89 | EUR 51.28M | EUR 386.76M | EUR 378.33M |
| FY2022 | EUR 769.50M | -EUR 41.12M | -EUR 20.08M | 72.6% | -3.25 | EUR 41.68M | EUR 311.85M | EUR 379.57M |
| FY2021 | n/a | n/a | n/a | n/a | 2.58 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | EUR 82.68M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
| Year | Dividends/share |
|---|---|
| FY2024 | 0.5 EUR |
| FY2023 | 0.5 EUR |
| FY2022 | 0.85 EUR |
| FY2021 | 0.7 EUR |
About Guerbet
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Guerbet's market cap?
Guerbet's market capitalization is EUR 82.68M.
What does Guerbet do?
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.